JP2025505652A - 非小細胞肺がんの治療における使用のための併用療法 - Google Patents

非小細胞肺がんの治療における使用のための併用療法 Download PDF

Info

Publication number
JP2025505652A
JP2025505652A JP2024546456A JP2024546456A JP2025505652A JP 2025505652 A JP2025505652 A JP 2025505652A JP 2024546456 A JP2024546456 A JP 2024546456A JP 2024546456 A JP2024546456 A JP 2024546456A JP 2025505652 A JP2025505652 A JP 2025505652A
Authority
JP
Japan
Prior art keywords
approximately
dose
antigen
weeks
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024546456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505652A5 (cg-RX-API-DMAC7.html
Inventor
マリオ・フィリヨン
ジュリー・ローリン
ジャック・ジョリヴェ
Original Assignee
アレシア・バイオセラピューティクス・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレシア・バイオセラピューティクス・インコーポレーテッド filed Critical アレシア・バイオセラピューティクス・インコーポレーテッド
Publication of JP2025505652A publication Critical patent/JP2025505652A/ja
Publication of JP2025505652A5 publication Critical patent/JP2025505652A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2024546456A 2022-02-07 2023-02-06 非小細胞肺がんの治療における使用のための併用療法 Pending JP2025505652A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263307533P 2022-02-07 2022-02-07
US63/307,533 2022-02-07
US202263333597P 2022-04-22 2022-04-22
US63/333,597 2022-04-22
PCT/CA2023/050151 WO2023147673A1 (en) 2022-02-07 2023-02-06 Combination therapy for use in treatment of non-small cell lung cancer

Publications (2)

Publication Number Publication Date
JP2025505652A true JP2025505652A (ja) 2025-02-28
JP2025505652A5 JP2025505652A5 (cg-RX-API-DMAC7.html) 2026-02-13

Family

ID=87553087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024546456A Pending JP2025505652A (ja) 2022-02-07 2023-02-06 非小細胞肺がんの治療における使用のための併用療法

Country Status (9)

Country Link
US (1) US20250108110A1 (cg-RX-API-DMAC7.html)
EP (1) EP4475885A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505652A (cg-RX-API-DMAC7.html)
KR (1) KR20240153627A (cg-RX-API-DMAC7.html)
AU (1) AU2023216333A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243096A1 (cg-RX-API-DMAC7.html)
IL (1) IL314600A (cg-RX-API-DMAC7.html)
MX (1) MX2024009671A (cg-RX-API-DMAC7.html)
WO (1) WO2023147673A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2928846A1 (en) * 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
CA2862739A1 (en) * 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
EP4329801A4 (en) * 2021-04-27 2025-05-14 Alethia Biotherapeutics Inc. Method for allowing immune cells infiltration in tumors

Also Published As

Publication number Publication date
IL314600A (en) 2024-09-01
WO2023147673A1 (en) 2023-08-10
AU2023216333A1 (en) 2024-08-22
CA3243096A1 (en) 2023-08-10
MX2024009671A (es) 2024-08-19
EP4475885A4 (en) 2026-02-18
KR20240153627A (ko) 2024-10-23
EP4475885A1 (en) 2024-12-18
US20250108110A1 (en) 2025-04-03

Similar Documents

Publication Publication Date Title
JP2020524698A (ja) がんの処置における使用のためのIL−1β結合性抗体
KR20180101584A (ko) 항-pd-1 항체 및 또 다른 항암제의 조합을 사용하는 폐암의 치료
CA2638040A1 (en) Treatment of metastatic breast cancer
KR20190015407A (ko) 재발성 소세포 폐암의 치료 방법에 사용하기 위한 항-pd-1 항체
US20240317884A1 (en) Method for allowing immune cells infiltration in tumors
WO2012119077A1 (en) Co -administration of eribulin and farletuzumab for the treatment of breast cancer
Lemech et al. A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
JP2022512866A (ja) がんを処置するための抗lag3抗体の投薬レジメンおよび抗pd-1抗体との組み合わせ治療
JP2014527035A (ja) 婦人科悪性腫瘍を治療するためのパクリタキセルとの組み合わせの抗ErbB3抗体
WO2022089377A1 (en) Combination of a pd-1 or pd-l1 antagonist and a vegfr inhibitor for treating cancer
US20250108110A1 (en) Combination therapy for use in treatment of non-small cell lung cancer
JP2024509914A (ja) ニューレグリン1(nrg1)遺伝子融合に関連する腫瘍を処置するための抗erbb3(her3)モノクローナル抗体の投与量および投与
CN118900700A (zh) 用于治疗非小细胞肺癌的联合疗法
US20260116977A1 (en) Methods of treating melanoma using an anti-ctla4 antibody
TW202436335A (zh) 治療表現dll3的癌症之方法
JP2025511396A (ja) 固形腫瘍の治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260204